Microsoft word - bornhop_ed_24-10_abstract.docx

Séminaires & Conférences Chimie École Doctorale 459 Salle de Cours SC-16.01 – Université Montpellier II
An ultra-sensitive, low-volume, free-solution,
label-free chemical sensing platform
Prof. Darryl J. BORNHOP
Department of Chemistry, The Vanderbilt Institute for Chemical Biology, and Vanderbilt Ingram Cancer Center; Vanderbilt University and Vanderbilt University Medical Center, Nashville TN, 37235 Back-scattering interferometry (BSI) is a universal sensing platform with ultrahigh sensitivity (zeptomole) and picoliter detection volumes. It has a simple optical train, consisting of a coherent source, microfluidic chip and detector. This overview presentation will teach how BSI works and show it is a tool that can be widely used across scientific disciplines. For example it will be shown that a unique multi-pass configuration allows BSI to transduce minute changes in the refractive index of a solution into equilibrium binding constants over a range of at least six orders of magnitude,[1,2] without any labeling and in free-solution. Quantification at the level of femtomolar concentrations in complex milieu will be demonstrated, as will the quantification of binding affinity for antibody-antigen,[2] protein-ion, protein-protein, and aptamer-protein-aptamer interactions.[3] Respiratory virus RNA detection investigations will illustrate that BSI measures conformational changes and can be a quite sensitive detector.[4] Then, DNA hybridization determinations and sugar-lectin binding studies[5] will illustrate that BSI is not limited by mass sensitivity as with other ‘bio’-sensors, and lends insights into multivalent interactions, while quantifying the influence of labels and/or surface immobilization. Next, direct quantification of binding affinities for membrane-associated protein drug targets in native bilayer environments[6] will show BSI has allowed characterization molecular mechanism studies[7] and the quantification of allosteric binding in CXCR-4.[8] Finally, work on hydrogen bonding studies in non-aqueous media[8] will show more general applicability of BSI, while investigations toward near-patient diagnostics and biomarker validation provides evidence it is a quantitative sensor with significant advantages in biomarker validation. References
1. Free-Solution, Label-Free Molecular Interactions Studied by Back-scattering Interferometry. D.J. Bornhop, J.C.
Latham, A. Kussrow, D.A. Markov, R.D. Jones, and H.S. Sørensen, Science, Sept. 21; 317(5845): 1732-1736, (2007). 2. Universal Sensing by Transduction of Antibody Binding using Backscattering Interferometry. A. Kussrow, M.
M. Baksh, D.J. Bornhop, M.G. Finn, ChemBioChem, 12(3):367-70 (2011). 3. Measurement of Aptamer-Protein Interactions with Back-scattering Interferometry. I.R. Olmsted, Y. Xiao, M.
Cho, A. Csordas, J.H. Sheehan, J. Meiler, H.T. Soh, D.J. Bornhop, Analytical Chemistry, 83(23): 8867-70 (2011). 4. The effect of hybridization-induced secondary structure alterations on RNA detection using backscattering
interferometry, N. Adams, I. Olmsted, F. Haselton, D.J. Bornhop, D. Wright, Nucleic Acids Research, 41(9): e103 (2013). 5. Comparison of Free-solution and Surface-immobilized Molecular Interactions using a Single Platform,
Backscattering Interferometry. I. R. Olmsted, A. Kussrow, and D. J. Bornhop, Analytical Chemistry, 84(24): 10817-22 (2012). 6. Quantitation of Membrane-Ligand Interactions Using Backscattering Interferometry. M.M. Baksh, A. Kussrow,
M. Mileni, M.G. Finn, D. J. Bornhop, Nature Biotechnology, 29(4): 357-60 (2011). (The Economist, June 4-10, 2011) 7. Baclofen and other GABAB receptor agents are allosteric modulators of the CXCL12 chemokine receptor
CXCR4. A. Guyon, A. Kussrow, I. Olmsted, D. J. Bornhop and J-L. Nahon, Journal of Neuroscience, July 10; 33(28): 11643-11654 (2013). PMID: 23843532 8. Study of Hydrogen Binding Interactions in Acetonitrile using Back-scattering Interferometry. E.N. Presciotta,
D.J. Bornhop, R.A. Flowers, Organic Letters, 13(10): 2654-7 (2011).


Guidelines for inpatient diabetes management.xls

GUIDELINES FOR INPATIENT DIABETES MANAGEMENT These recommendations do not take into account individual patient situations, and do not substitute for clinical judgment. Changes in diet, activity, medications (i.e.: steroids), and acuity of illness (i.e.: infection, renal insufficiency) may quickly change treatment requirements Inpatient Blood Glucose Targets: 80-180mg/dL (In the ICU s

Microsoft word - cv_lozzi.doc

Curriculum Professionale ------------------------------------------------------------------------------------------------------------------------ Luogo e data di nascita: Roma, 06/07/1975 ------------------------------------------------------------------------------------------------------------------------ Luglio 2002 . Laurea in Medicina e Chirurgia presso L’Università degli Studi d

Copyright © 2010-2014 Drug Shortages pdf